arrow
X

Xiaoyan Liu

huazhong university of science technology
H指数:31
被引数:2,628

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer

IMscin002研究:非小细胞肺癌患者对阿替利珠单抗皮下给药与静脉给药的偏好探索性分析

2025-11-260
OAAI
Safety and short-term outcomes of lecanemab for Alzheimer’s disease in China: a multicentre study

Li, L.L.; Wang, R.Z.; Wang, Z.; Hu, H.; Xu, W.; Zhu, L.; Sun, Y.; Chen, K.L.; Chen, S.F.; He, X.Y.; et al. 利卡奈单抗治疗阿尔茨海默病在中国的安全性与短期疗效:一项多中心研究。Brain 2025, epub ahead print. [Google Scholar] [CrossRef] [PubMed]

Brain
IF11.7
2025-11-110
OA
A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy

一项关于pembrolizumab联合plinabulin和docetaxel治疗既往接受过治疗并接受过免疫治疗(Anti-PD-1/PD-L1抑制剂)单药或联合铂类双药化疗后疾病进展(PD)的转移性非小细胞肺癌患者的2期研究。

2025-02-010
OAAI